143 related articles for article (PubMed ID: 16172899)
1. (99m)Tc-rituximab radiolabelled by photo-activation: a new non-Hodgkin's lymphoma imaging agent.
Stopar TG; Mlinaric-Rascan I; Fettich J; Hojker S; Mather SJ
Eur J Nucl Med Mol Imaging; 2006 Jan; 33(1):53-9. PubMed ID: 16172899
[TBL] [Abstract][Full Text] [Related]
2. 99mTc-labelled rituximab, a new non-Hodgkin's lymphoma imaging agent: first clinical experience.
Gmeiner Stopar T; Fettich J; Zver S; Mlinaric-Rascan I; Hojker S; Socan A; Peitl PK; Mather S
Nucl Med Commun; 2008 Dec; 29(12):1059-65. PubMed ID: 18987526
[TBL] [Abstract][Full Text] [Related]
3. ⁹⁹mTc carbonyl DTPA-rituximab: preparation and preliminary bioevaluation.
Pandey U; Kameswaran M; Dev Sarma H; Samuel G
Appl Radiat Isot; 2014 Apr; 86():52-6. PubMed ID: 24486518
[TBL] [Abstract][Full Text] [Related]
4. Radiolabeling of rituximab with (188)Re and (99m)Tc using the tricarbonyl technology.
Dias CR; Jeger S; Osso JA; Müller C; De Pasquale C; Hohn A; Waibel R; Schibli R
Nucl Med Biol; 2011 Jan; 38(1):19-28. PubMed ID: 21220126
[TBL] [Abstract][Full Text] [Related]
5. (99m)Tc(CO)(3)-Ibritumomab tiuxetan; a novel radioimmunoimaging (RII) agent of B cell non-Hodgkin's lymphoma (NHL).
Shah SQ; Khan AU; Khan MR
Biol Chem; 2012 Jan; 393(1-2):71-5. PubMed ID: 22628300
[TBL] [Abstract][Full Text] [Related]
6. Kit preparation and biokinetics in women of 99mTc-EDDA/HYNIC-E-[c(RGDfK)]2 for breast cancer imaging.
Ortiz-Arzate Z; Santos-Cuevas CL; Ocampo-García BE; Ferro-Flores G; García-Becerra R; Estrada G; Gómez-Argumosa E; Izquierdo-Sánchez V
Nucl Med Commun; 2014 Apr; 35(4):423-32. PubMed ID: 24335877
[TBL] [Abstract][Full Text] [Related]
7. Preparation & in vitro evaluation of ⁹⁰Y-DOTA-rituximab.
Kameswaran M; Pandey U; Dash A; Samuel G; Venkatesh M
Indian J Med Res; 2016 Jan; 143(1):57-65. PubMed ID: 26997015
[TBL] [Abstract][Full Text] [Related]
8. Preliminary evaluation of the potential of 99mTc carbonyl-DTPA-Rituximab as a tracer for sentinel lymph node detection.
Kameswaran M; Subramanian S; Pandey U; Samuel G
Appl Radiat Isot; 2016 Jan; 107():195-198. PubMed ID: 26524405
[TBL] [Abstract][Full Text] [Related]
9. (99m)Tc-labeled rituximab for imaging B lymphocyte infiltration in inflammatory autoimmune disease patients.
Malviya G; Anzola KL; Podestà E; Laganà B; Del Mastro C; Dierckx RA; Scopinaro F; Signore A
Mol Imaging Biol; 2012 Oct; 14(5):637-46. PubMed ID: 22127469
[TBL] [Abstract][Full Text] [Related]
10. (99m)Tc human IgG radiolabelled by HYNIC. Biodistribution and scintigraphy of experimentally induced inflammatory lesions in animal model.
Karczmarczyk U; Markiewicz A; Mikołajczak R; Lisiak E; Bilski M; Pietrzykowski J; Michalik J
Nucl Med Rev Cent East Eur; 2004; 7(2):107-12. PubMed ID: 15968595
[TBL] [Abstract][Full Text] [Related]
11. Clinical Evaluation of 99mTc-Rituximab for Sentinel Lymph Node Mapping in Breast Cancer Patients.
Li N; Wang X; Lin B; Zhu H; Liu C; Xu X; Zhang Y; Zhai S; OuYang T; Li J; Yang Z
J Nucl Med; 2016 Aug; 57(8):1214-20. PubMed ID: 26985055
[TBL] [Abstract][Full Text] [Related]
12. Radiolabelling rituximab with (99m)Tc in three steps procedure.
Fontan C; Bezombes C; Salabert AS; Costes J; Lopez R; Fournie JJ; Avet-Loiseau H; Coulais Y; Payoux P; Tafani M
J Labelled Comp Radiopharm; 2015 Jun; 58(7):274-80. PubMed ID: 26017396
[TBL] [Abstract][Full Text] [Related]
13. [Preliminary study on a new sentinel lymphoscintigraphy agent 99mTc-Rituximab for breast patient].
Wang XJ; Lin BH; Yang Z; Ouyang T; Li JF; Xu B; Zhang Y; Zhang MY
Zhonghua Zhong Liu Za Zhi; 2006 Mar; 28(3):200-3. PubMed ID: 16875605
[TBL] [Abstract][Full Text] [Related]
14. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
15. Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.
Ogura M; Ando K; Taniwaki M; Watanabe T; Uchida T; Ohmachi K; Matsumoto Y; Tobinai K;
Cancer Sci; 2011 Sep; 102(9):1687-92. PubMed ID: 21624007
[TBL] [Abstract][Full Text] [Related]
16. An approach for conjugation of (177) Lu- DOTA-SCN- Rituximab (BioSim) & its evaluation for radioimmunotherapy of relapsed & refractory B-cell non Hodgkins lymphoma patients.
Thakral P; Singla S; Yadav MP; Vasisht A; Sharma A; Gupta SK; Bal CS; ; Malhotra A
Indian J Med Res; 2014 Apr; 139(4):544-54. PubMed ID: 24927340
[TBL] [Abstract][Full Text] [Related]
17. [Expression of CD16zeta in NK cells of B-cell non-Hodgkin's lymphoma patients and in vitro killing effect of rituximab combined lymphokine-activated killer cells on B-NHL cells].
Shi YX; Zhang XS; Xia JC; Li YQ; Xu RH; Han WJ; Zhang JH; Guan ZZ; Jiang WQ
Ai Zheng; 2007 Aug; 26(8):837-42. PubMed ID: 17697543
[TBL] [Abstract][Full Text] [Related]
18. Initial clinical results with technetium-99m-labeled LL2 monoclonal antibody fragment in the radioimmunodetection of B-cell lymphomas.
Baum RP; Niesen A; Hertel A; Adams S; Kojouharoff G; Goldenberg DM; Hör G
Cancer; 1994 Feb; 73(3 Suppl):896-9. PubMed ID: 8306276
[TBL] [Abstract][Full Text] [Related]
19. Investigation of 99mTc-labelling of recombinant human interleukin-2 via hydrazinonicotinamide.
Karczmarczyk U; Garnuszek P; Maurin M; Di Gialleonardo V; Galli F; Signore A; Mikołajczak R
Nucl Med Biol; 2010 Oct; 37(7):795-803. PubMed ID: 20870154
[TBL] [Abstract][Full Text] [Related]
20. Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma.
Leahy MF; Seymour JF; Hicks RJ; Turner JH
J Clin Oncol; 2006 Sep; 24(27):4418-25. PubMed ID: 16940276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
